España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

acino ag - celecoxib - cÁpsula dura - 200 mg - celecoxib 200 mg - celecoxib

Unión Europea - español - EMA (European Medicines Agency)

acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - agentes antitrombóticos - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Unión Europea - español - EMA (European Medicines Agency)

bayer ag - octocog alfa - hemofilia a - antihemorrágicos - tratamiento y profilaxis de hemorragias en pacientes con hemofilia a (deficiencia congénita de factor viii). iblias puede ser utilizado para todos los grupos de edad.

Unión Europea - español - EMA (European Medicines Agency)

bayer ag - octocog alfa - hemofilia a - antihemorrágicos - tratamiento y profilaxis de hemorragias en pacientes con hemofilia a (deficiencia congénita de factor viii). kovaltry se puede utilizar para todos los grupos de edad.

Unión Europea - español - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - agentes antitrombóticos - xarelto, co-administrado con ácido acetilsalicílico (aas), solos o con aas más clopidogrel o ticlopidina, está indicado para la prevención de eventos aterotrombóticos en pacientes adultos después de un síndrome coronario agudo (sca) con elevación de biomarcadores cardiacos. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prevención del tromboembolismo venoso (tev) en pacientes adultos sometidos a cirugía electiva de reemplazo de cadera o rodilla. tratamiento de la trombosis venosa profunda (tvp) y embolia pulmonar (pe), y la prevención de la recurrencia de la tvp y de la ep en los adultos. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Cuba - español - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

novartis pharma stein ag. - everolimus - comprimido - 2,5 mg

Cuba - español - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

novartis pharma stein ag. - everolimus - comprimido - 10 mg

Cuba - español - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

novartis pharma stein ag. - everolimus - comprimido - 5 mg

Unión Europea - español - EMA (European Medicines Agency)

bayer ag - darolutamide - próstata neoplasias, resistente a la castración - terapia endocrina - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.

Unión Europea - español - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarreicos, antiinflamatorio intestinal / contra la infección de los agentes - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.